A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer. The researchers will also look at whether cemiplimab and fianlimab given before a nephrectomy is a safe and effective treatment approach and if there is a change in the size of the tumor following immunotherapy prior to planned surgery.

Trial Details

NCT ID
NCT06699602
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Cemiplimab
  • Fianlimab
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Age ≥ 18 years at the time of informed consent.
  • Patient must be able to provide informed consent, or a legal authorized representative (LAR) must be identified to provide consent in cases where t…
  • Signed and dated IRB-approved Informed Consent Form
  • Patients must be planned for nephrectomy for high risk non-metastatic clear cell renal cell carcinoma.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →